Anti-Angiogenic Therapy in Renal Cell Carcinoma

Title: Anti-Angiogenic Therapy in Renal Cell Carcinoma

Volume: 5 Issue: 1

Author(s): Shree G. Sharma, Sudip Nanda and Santo Longo

Affiliation:

Keywords: Angiogenesis, renal cell carcinoma, VHL, VEGF, sorafenib, sumitinib, bevacizumab, temsirolimus, mTOR, angiopoietins

Abstract: Renal cell carcinoma (RCC) is one of the most common cancers in the United States. Recent achievements in translational research have lead to significant developments in treatment strategies for this malignancy. RCC is a richly vascular neoplasm. A better understanding of its biology has helped in the development of antiangiogenic therapy. Vascular endothelial growth factor (VEGF) is the most important molecular target in the treatment of RCC. Patents have been filed for anti-VEGF and other molecular pathways involved in the pathogenesis of RCC.

Cite this article as:

Sharma G. Shree, Nanda Sudip and Longo Santo, Anti-Angiogenic Therapy in Renal Cell Carcinoma, Recent Patents on Anti-Cancer Drug Discovery 2010; 5 (1) . https://dx.doi.org/10.2174/157489210789702181